Dr. Chan co-founded Morningside, a diversified investment group engaged primarily in private equity and venture capital investments in North America, Asia and Europe. Morningside commenced investing in China in 1992 and remains active in China\u00e2\u20ac\u2122s internet, media and life sciences sectors. Dr. Chan is a director of publicly listed Hang Lung Group Limited, a Hong Kong property holding company, and serves on the boards of several private biotechnology companies including CellCentric, Stealth Peptides, and Vaccine Technologies Inc. Dr. Chan is a trustee of Fudan University in Shanghai and sits on many advisory boards such as the International Society of Stem Cell Research Global Advisory Council, Cold Spring Harbor Conferences Asia, International Board of Governors of the New York Academy of Sciences and the Physical Sciences Visiting Committee of UCLA. Dr. Chan received his BS and MS degrees in Engineering from UCLA, and a Master of Science degree in Medical Radiological Physics and a Doctor of Science degree in Radiation Biology from Harvard University. He completed his post-doctoral training at the Dana Farber Cancer Institute.<\/p>\n